Spyre Therapeutics (SYRE) Receivables (2015 - 2024)

Spyre Therapeutics (SYRE) reported Receivables of $5.9 million for Q4 2024, little changed quarter-over-quarter from $5.9 million in Q3 2024.

Spyre Therapeutics (SYRE) Receivables (2015 - 2024) Analysis & Trends

Spyre Therapeutics has reported Receivables for 5 years, with the latest figure at $5.9 million in Q4 2024.

For the quarter ending Q4 2024, Receivables changed N/A year-over-year to $5.9 million; the trailing twelve-month figure through Dec 2024 stood at $5.9 million (changed N/A YoY), and the FY2024 full-year result was $5.9 million, changed N/A from the prior year.
Receivables for Q4 2024 stood at $5.9 million, roughly flat from $5.9 million in the prior quarter.
The five-year high for Receivables was $21.5 million in Q1 2021, with the low at $5.9 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Spyre Therapeutics	6.95 Bn	6.95 Bn	-	-

Download Data